Scientists try to 'Clean' donor kidneys of hidden virus before transplant

NCT ID NCT07488481

Summary

This early safety trial tests whether treating donor kidneys with an experimental compound called SYN002 during organ preservation can reduce transmission of cytomegalovirus (CMV) to transplant recipients. The study involves 12 patients receiving kidneys from donors known to carry latent CMV. Researchers will assess whether the treatment is safe and whether it decreases the amount of virus transmitted after transplantation.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Health Network, Toronto General Hospital, Ajmera Transplant Centre

    Toronto, Ontario, M5G 2N2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.